## FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, [	D.C.	20549
---------------	------	-------

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Velleca Mark A.</u>						2. Issuer Name and Ticker or Trading Symbol G1 Therapeutics, Inc. [ GTHX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
					٦									X	Directo	or 10%		10% Ov	vner	
(Last)	(F	irst)	(Middle)	)	_									X	Officer below)	(give title		Other (s below)	specify	
C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR.						3. Date of Earliest Transaction (Month/Day/Year) 03/15/2018								President and CEO						
4501 RE	SEARCH (	COMMONS, SU	ITE 1	00																
(Street) RESEARCH					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person						
TRIANGLE NC 27709 PARK												Λ		iled by Mor		than One Reporting				
(City)	(S	tate)	(Zip)																	
		Tab	le I - 1	Non-Deri	vative	Sec	uriti	ies A	cquire	d, D	isposed c	of, or B	enefici	ally	Owned	l				
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/Y				Execution Date		cution Date, y		ction Instr.				nd 5) Secui Bene Owne		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	ted action(s) 3 and 4)			(Instr. 4)		
Common Stock 03/15/201					.018	18		M <sup>(1)</sup>		7,500	A	\$3.7	72		7,500		D			
Common Stock 03/15/20			.018	18		S <sup>(1)</sup>		7,500	D	\$38.19	55 <sup>(2)</sup>	0.00			D					
		7	able								posed of , converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	if any	eemed tion Date, n/Day/Year)	4. Transa Code ( 8)			vative urities uired or oosed O) tr. 3, 4	6. Date Expira (Month	tion Da		7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)		De Se (In	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amoun or Numbe of Shares	r						
Stock Options (Right to	\$3.72	03/15/2018			M <sup>(1)</sup>			7,500	(3	)	12/21/2025	Common	n 7,500		\$0.00	159,433	3	D		

## **Explanation of Responses:**

- 1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- 2. The price represents the weighted average price with a low of \$38.00 and a high of \$38.42.
- 3. The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

## Remarks:

/s/ Peter N. Cunningham, attorney-in-fact

03/16/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.